<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Breast implant infections</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Breast implant infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Breast implant infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tahaniyat Lalani, MBBS, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael R Zenn, MD, FACS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandra Nelson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Augmentation mammoplasty with prosthetic breast implantation is a common surgical procedure used for breast enlargement, for correction of asymmetries, or for reconstruction after mastectomy [<a href="#rid1">1</a>]. In 2019, in the United States, more than 290,000 procedures were performed; this figure represents a 37 percent increase from 2000 [<a href="#rid2">2</a>]. Breast implants are performed both for breast enlargement, as above, and, in women who have undergone mastectomy either for breast cancer or for risk reduction, as part of breast reconstruction. </p><p>Today, silicone implants are the implant type used by most surgeons. Saline-filled breast implants used to be the main prostheses used for breast augmentation. Although silicone gel implants provide a more natural appearance and feel, unfounded concerns about risk of connective tissue disease associated with silicone implants led to a moratorium on their use in the United States in 1992. This was lifted in November 2006, after further studies led to the conclusion that silicone gel implants expose patients to no demonstrable risk for connective tissue or rheumatologic disease. (See  <a class="medical medical_review" href="/z/d/html/96116.html" rel="external">"Implant-based breast reconstruction and augmentation"</a>.)</p><p>Both silicone and <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> implants have the disadvantages that additional surgery may be necessary, since the implants do not last a lifetime, and that periodic imaging studies may be needed to determine if implant rupture has occurred. </p><p>Breast implants in reconstruction are sometimes placed following the use of a tissue expander. In addition, acellular dermal matrix is often used as an adjunct to tissue expander in breast implant reconstructions. This matrix may assist in the shaping of the reconstructed breast and allow either one-stage breast reconstruction with implants or tissue expanders to be filled to higher volumes [<a href="#rid3">3</a>].</p><p>Issues related to breast implant infections will be reviewed here. Breast cellulitis, which is another form of breast infection related to breast cancer surgery, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/797.html" rel="external">"Breast cellulitis and other skin disorders of the breast"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">INCIDENCE AND RISK FACTORS</span><span class="headingEndMark"> — </span>The risk of infection following breast reconstruction is difficult to estimate due to the lack of high-quality, active surveillance data. Infection rates of 0.2 to 3.2 percent of implanted breasts have been reported in retrospective studies utilizing medical record data, and these studies have methodologic limitations including the heterogeneity of the patient population (eg, post-mastectomy reconstruction versus aesthetic augmentation), surgical procedures (implants versus tissue expanders), and durations of follow-up [<a href="#rid4">4-6</a>]. </p><p>Risk factors for infection associated with breast implants have not been adequately assessed in prospective studies with long-term follow-up [<a href="#rid7">7</a>]. In addition, the available data do not permit adequate evaluation of the relative importance of risk factors. Despite these limitations, the following factors are thought to be determinants of the risk of infection [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Surgical technique appears to be important, with a higher infection risk with periareolar and transareolar approaches compared with breast implant insertion through inframammary incisions, as endogenous flora in the nipple area may contaminate the implant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breast reconstruction using implants after mastectomy is associated with as much as a 10-fold increase in the rate of infection compared with breast augmentation alone [<a href="#rid8">8-10</a>]. In a study of over 18,000 commercially insured women who underwent mastectomy between 2004 and 2011, the overall incidence of surgical site infection within 180 days of surgery was 10.3 percent following mastectomy plus breast implantation (compared with 5.1 percent following mastectomy only and 10.7 percent following mastectomy plus flap) [<a href="#rid10">10</a>]. The higher risk with breast reconstruction may be related to the length of procedures, lymph node dissection, tissue scarring, and skin atrophy resulting from prior cancer surgery and radiation therapy [<a href="#rid7">7,11,12</a>]. Acellular dermal matrix use during reconstruction, type II diabetes, and lower median household income (USD &lt;$50,000) are additional risk factors reported in observational studies and a meta-analysis [<a href="#rid13">13-16</a>].</p><p></p><p class="bulletIndent1">For women undergoing mastectomy with immediate reconstruction (compared with delayed) with implant placement, there is an increased association with infection, perhaps due to contamination of the operative field with endogenous flora during one-stage procedures [<a href="#rid10">10,12</a>]. As an example, in a multistate retrospective cohort study that included over 10,000 women who had reconstruction after mastectomy, the risk of surgical site infection was highest with immediate reconstruction (breast implants, tissue expanders, or immediate repair with autologous tissue within seven days, 8.9 percent risk), followed by delayed reconstruction after seven days (5.7 percent risk), followed by secondary reconstruction (immediate reconstruction followed by additional reconstruction more than seven days later, 3.2 percent risk) [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">Despite this, immediate breast reconstruction remains the more common approach [<a href="#rid17">17,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of acellular dermal matrix as an adjunct to the placement of an implant or tissue expander is associated with higher rates of seroma formation and surgical site infections. In one meta-analysis, acellular dermal matrix use was associated with infection (odds ratio [OR] 1.47, 95% CI 1.04-2.06) but not explantation (OR 1.37, 95% CI 0.89-2.11) [<a href="#rid19">19</a>].</p><p></p><p>The origin of individual implant-associated infection is often difficult to determine. The major causes are thought to be contamination from endogenous flora in early-onset infections, while seeding of the implant due to secondary bacteremia from remote sites may be important in some late infections [<a href="#rid7">7,9</a>].</p><p>Rarely, breast implant infections have resulted from contaminated implants or the use of contaminated <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or contaminated marking solution [<a href="#rid20">20-23</a>]. (See <a class="local">'Microbiology and epidemiology of infection'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h1">MICROBIOLOGY AND EPIDEMIOLOGY OF INFECTION</span><span class="headingEndMark"> — </span>Acute and subacute breast implant infections are commonly due to gram-positive pathogens such as coagulase-negative staphylococci, <em>Cutibacterium</em> species, <em>Staphylococcus aureus</em>, and streptococci. However, gram-negative bacteria including <em>Pseudomonas</em> and anaerobes are also important pathogens in many case series [<a href="#rid9">9,24-27</a>]. In a French cohort, <em>Pseudomonas</em> was the second most commonly isolated pathogen in both early and late infection after <em>S. aureus</em> [<a href="#rid25">25</a>]. Case reports of implant infections due to opportunistic pathogens (eg, <em>Prototheca wickerhamii</em>, <em>Scedosporium apiospermum</em>) and atypical exposures (eg, <em>Pasteurella multocida</em> from a cat scratch, <em>Campylobacter fetus</em> from eating undercooked meat) have been reported and should be considered in immunocompromised hosts and patients not responding to empiric antibiotic therapy [<a href="#rid28">28-32</a>]. </p><p>Implant-associated infections due to nontuberculous mycobacteria usually become apparent several weeks to several months following surgery. Typical clinical features include failure of the primary incision to heal or early dehiscence of a portion of the incision and odorless serous or seropurulent drainage of fluid that is culture-negative on routine bacterial cultures. Acid-fast stains and cultures should be obtained in all cases of subacute infection, even when routine culture reveals skin flora.</p><p>Contaminated skin marking solution and tap water have been implicated as potential sources in small outbreaks of nontuberculous mycobacterial infections [<a href="#rid23">23,33</a>], but a source is not identified in most cases [<a href="#rid34">34</a>].</p><p>In another small outbreak, black sediment in the <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> implants of patients undergoing revision surgery was due to contamination with <em>Curvularia</em> [<a href="#rid20">20</a>]. This dematiaceous mold was isolated from the sterile supply room where saline used to fill implants had been stored in bottles under a water-damaged ceiling.</p><p class="headingAnchor" id="H20460168"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H20460176"><span class="h2">General principles of implant infection</span><span class="headingEndMark"> — </span>The pathogenesis of prosthetic implant infections involves a complex interaction between the host, the device, and the bacteria causing the infection. In animal models, the presence of a subcutaneous foreign body reduces the minimal inoculum of <em>S. aureus</em> required to cause infection by a factor of more than 100,000, to as little as 100 colony-forming units [<a href="#rid35">35</a>]. At least two factors contribute to this increase in risk: foreign bodies do not have a microcirculation, which is crucial for both host defense and the delivery of antibiotics [<a href="#rid35">35</a>], and the interaction of neutrophils with the foreign body can induce a neutrophil defect that may enhance the susceptibility to infection [<a href="#rid36">36</a>].</p><p>Adherent bacteria multiply and elaborate exopolysaccharides, also known as glycocalyx. Eventually, microcolonies of bacteria encased in glycocalyx coalesce to form a structure known as a biofilm [<a href="#rid37">37,38</a>].</p><p>A majority of implant infections are caused by microorganisms that grow in biofilms such as coagulase-negative staphylococci (eg, <em>Staphylococcus epidermidis</em>) and <em>S. aureus</em>. Microcolonies of bacteria in biofilms form complex communities, with intraspecies communication and adaptation through a process called quorum-sensing, which regulates both virulence and biofilm formation [<a href="#rid39">39</a>].</p><p>Bacteria near the surface of the biofilm are usually metabolically active and have access to nutrients that diffuse through the upper surface of the biofilm. In comparison, organisms deep within the biofilm are metabolically inactive or in various stages of dormancy and are protected from host defenses such as phagocytes and antimicrobial penetration. (See  <a class="medical medical_review" href="/z/d/html/7664.html" rel="external">"Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Biofilm'</a>.)</p><p class="headingAnchor" id="H20460198"><span class="h2">Microbiology of the breast</span><span class="headingEndMark"> — </span>The breast contains endogenous flora derived from the nipple ducts. Bacteria colonizing the nipple ducts may gain access to deeper breast tissue, particularly during surgical or biopsy procedures. In samples obtained from women undergoing breast augmentation or reduction, coagulase-negative staphylococci were the predominant organism, being isolated from 53 percent of specimens [<a href="#rid40">40</a>]. Other aerobic organisms, each of which was present in less than 10 percent of specimens, were diphtheroids, lactobacilli, enterococci, and alpha-hemolytic streptococci (3 percent). The major anaerobe was <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) <em>acnes</em>.</p><p>The endogenous flora can contaminate the prosthesis during implantation and be responsible for subsequent acute infections. (See <a class="local">'Clinical manifestations'</a> below.)</p><p class="headingAnchor" id="H20459910"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Breast implant infections usually present in a bimodal fashion: during the acute postoperative period (six days to six weeks after surgery) or with late onset (more than six months after surgery). In a single center study of 1473 breast cancer patients who underwent mastectomy and immediate implant-based breast reconstruction or placement of a tissue expander, the median time between surgery and infection was 70 days (interquartile range [IQR]: 34 to 190 days) [<a href="#rid5">5</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Early-onset infections of breast implants are typically associated with fever, breast pain, erythema, and purulent fluid or drainage at the site of the incision. However, some patients develop systemic signs and symptoms of infection at a time when the primary surgical site manifests little or no evidence of infection [<a href="#rid41">41</a>]. As an example, toxic shock syndrome is a rare complication in the early postoperative period; it results from <em>S. aureus</em> infection that is usually acquired during surgery [<a href="#rid7">7,42</a>]. Symptoms in patients with toxic shock syndrome may begin as early as 12 to 24 hours after surgery, but the median time is four days after surgery [<a href="#rid41">41</a>]. Despite the severe systemic manifestations, the surgical site typically shows neither inflammation nor purulence. (See  <a class="medical medical_review" href="/z/d/html/3161.html" rel="external">"Staphylococcal toxic shock syndrome"</a>.)</p><p></p><p class="bulletIndent1">Among individuals who underwent implantation using acellular dermal matrix, erythema of the breast within the first weeks postoperatively could also reflect "red breast syndrome." It can be distinguished from infection in that the erythema only overlies the acellular dermal matrix and leukocytosis or systemic signs of infection are absent. It is felt to be an immune response and is self-limited. One particular acellular dermal matrix, AlloDerm, appears to be the main culprit [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subacute infections usually present with chronic pain, persistent drainage of serous or purulent fluid, failure of a portion of the incision to heal or remain healed, and/or migration or extrusion of the implant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late infections, occurring several months to years after implantation, are rare and usually result from secondary bacteremia due to a focus of infection at another body site or an invasive procedure. Early treatment of any potentially severe bacterial infection may limit this risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The role of infection in the genesis of capsular contracture (contraction of the scar around the soft implant) is unproven but suggested by the high incidence of bacteria grown in culture from these capsules [<a href="#rid7">7,44,45</a>]. Some have proposed an important role for biofilm from coagulase-negative staphylococci [<a href="#rid46">46</a>]. (See <a class="local">'General principles of implant infection'</a> above.)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of breast implant infection is typically first suspected from the clinical features of fever and erythema of the breast. </p><p>If the breast increases in size or a seroma is suspected based on physical exam, ultrasonography should be performed to see if there is a fluid collection. If fluid is present, aspiration should be performed under ultrasound guidance, since blind aspiration may lead to perforation and leakage of the implant. Aspirated fluid should be sent for Gram stain, aerobic and anaerobic bacterial cultures, and fungal and acid-fast bacilli cultures. </p><p>If tissue is removed, it should be sent for histopathologic examination and cultures. Special stains to reveal acid-fast organisms should be routinely performed and a portion of the specimen should be sent for both bacterial and mycobacterial culture [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The initial treatment of breast implant infections is antibiotic therapy. In patients with deep infections, surgical intervention, including implant removal, is often necessary. There are no randomized trials or large cohort studies evaluating the management of breast implant infections, and our approach outlined below is based on small case series and clinical experience. </p><p>A systematic review of observational studies including 1044 patients found the following [<a href="#rid47">47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Twenty-nine percent of patients had a mild infection (ie, warmth, swelling, cellulitis) and were exclusively treated with antibiotics. Of these, 81 percent (95% CI:58 to 97) were successfully treated without surgical intervention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thirty-nine percent underwent a one-stage replacement, of whom 85 percent (95% CI: 75 to 92) were successfully treated without infection recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thirty-five percent underwent explantation, of which 39 percent (95% CI:24 to 55) had delayed reimplantation (mean duration between explantation and reimplantation was 5.75 months);five percent of patients who underwent delayed reimplantation experienced recurrence of infection requiring removal of implant. </p><p></p><p class="headingAnchor" id="H956680104"><span class="h2">Mild, superficial cellulitis</span><span class="headingEndMark"> — </span>Mild, superficial cellulitis describes patients with no systemic symptoms and with a limited area of erythema overlying the breast. </p><p class="headingAnchor" id="H4080383208"><span class="h3">Choice of antibiotics</span><span class="headingEndMark"> — </span>An empiric antibiotic regimen should include coverage for methicillin-resistant <em>S. aureus </em>(MRSA), coagulase-negative staphylococcus, and streptococci. A mild superficial cellulitis may be treated exclusively with oral antibiotics. For oral therapy, we prefer antibiotics such as <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (two double-strength tablets twice daily), <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (450 mg three times daily), or the combination of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg twice daily) and <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> (875 mg twice daily). </p><p class="headingAnchor" id="H104088535"><span class="h3">Response to therapy</span><span class="headingEndMark"> — </span>In cases of superficial infections that promptly respond to oral antibiotic therapy, therapy should be continued for 10 to 14 days. </p><p>A lack of response to therapy within 48 hours should prompt re-evaluation for deeper sites of infection and any need for surgical intervention or alterations of the antibiotic regimen. Patients initially treated with oral antibiotics should be changed to an intravenous regimen. (See <a class="local">'Extensive cellulitis and/or deep infections'</a> below.)</p><p class="headingAnchor" id="H1270973241"><span class="h2">Extensive cellulitis and/or deep infections</span><span class="headingEndMark"> — </span>Extensive cellulitis describes patients with a larger area of erythema overlying the breast with or without systemic symptoms. Deep infections involve the prosthesis with abscess or draining wound.</p><p class="headingAnchor" id="H3517253287"><span class="h3">Choice of antibiotics</span><span class="headingEndMark"> — </span>Extensive cellulitis and/or deeper infections should be treated with intravenous antibiotics. </p><p class="bulletIndent1"><span class="glyph">●</span>For patients with extensive cellulitis without involvement of the prosthesis, empiric therapy should include coverage for MRSA, coagulase-negative staphylococci, and streptococci. We prefer <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/484.html" rel="external">"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with involvement of the prosthesis, abscess, or draining wound, surgery is indicated and empiric antibiotics should target MRSA, coagulase-negative staphylococci, and streptococci. In this case, initial parenteral therapy is <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 1</a>). Based on the Gram stain or clinical suspicion of gram-negative organisms, vancomycin should be combined with a cephalosporin or fluoroquinolone with pseudomonal activity. (See <a class="local">'Indications for immediate surgical intervention'</a> below and  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antibiotics with antipseudomonal activity'</a>.)</p><p></p><p>Empiric antibiotic therapy can ultimately be tailored to target the organism(s) recovered at the time of surgery or from aspiration (if performed) based on culture and susceptibilities. If no gram-negative organisms are recovered on Gram stain or culture(s) remain negative, antibiotic therapy should be tailored to cover MRSA, coagulase-negative staphylococci, and streptococci. If <em>S. aureus</em> or coagulase-negative staphylococcus are cultured, we would add oral <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (600 mg daily) for biofilm coverage.</p><p class="headingAnchor" id="H1581947392"><span class="h3">Patients not requiring immediate surgical intervention</span><span class="headingEndMark"> — </span>For patients <strong>without</strong> systemic symptoms who have an extensive cellulitis and/or ultrasound findings of a fluid collection that is nonpurulent on aspiration, close observation on intravenous antibiotics is reasonable. For patients who have had aspiration of fluid, antibiotics can be tailored to culture results. If there is clinical response to initial therapy, patients can be switched to suitable oral alternatives as described above (see <a class="local">'Choice of antibiotics'</a> above). The duration of intravenous antibiotic therapy is usually 10 to 14 days. Surgical intervention is required for infections that do not resolve on intravenous antibiotics after 48 to 72 hours.</p><p class="headingAnchor" id="H3050790792"><span class="h3">Indications for immediate surgical intervention</span><span class="headingEndMark"> — </span>For patients <strong>with</strong> systemic signs of infection and extensive cellulitis, or drainage from a wound that connects to the implant, purulent drainage from ultrasound-guided aspiration, threatened implant exposure, or wound breakdown, immediate surgical intervention is warranted. </p><p class="headingAnchor" id="H2009710799"><span class="h4">Surgical intervention</span><span class="headingEndMark"> — </span>The intent of surgery is to drain purulent fluid, resect necrotic tissue, and explore the condition of the pocket to determine if it would be possible to immediately replace an implant (one-stage replacement). Otherwise, the implant is removed with a plan for delayed reimplantation. A third approach is explantation of infected material and immediate autologous free flap breast reconstruction. This approach has been used in patients at high risk for prosthetic-related complications (eg, morbidly obese, undergoing radiation or chemotherapy for breast cancer) [<a href="#rid48">48,49</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>One-stage replacement</strong> – In the absence of purulent, malodorous discharge and granulation tissue in the pocket, a one-stage implant replacement followed by antibiotic therapy is usually attempted in order to prevent the discomfort, cost, and disability required for removal, treatment, and delayed replacement of a new implant. If a decision is made to pursue a one-stage replacement, close follow-up is necessary to assure that adequate resolution of all signs of infection occurs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed implantation</strong> – Findings that would favor immediate implant removal with a need for delayed reimplantation would be malodorous or frankly purulent discharge and granulation tissue in the pocket. In the case of sepsis, the implant is removed and the wound left open to expedite resolution of the infection. Reimplantation would be considered months later when all edema has resolved.</p><p></p><p class="bulletIndent1">Additionally, conversion from a one-stage replacement to delayed implantation is necessary if any of the following factors occur over the course of the infection:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nontuberculous mycobacterial infection (see  <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Treatment'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fungal infections</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prompt and lasting response to antibiotic therapy has not occurred</p><p></p><p>The timing of reimplantation if a two-stage replacement is being attempted is dependent upon the degree of infection and the causative organism [<a href="#rid7">7</a>]. Some experts recommend four to six months or more before reimplantation, although there are no published trials to support this approach. </p><p>A specialized wound vac dressing that facilitates instillation of antimicrobial solutions for 7 to 10 days before reimplantation has been studied in several small uncontrolled case series of patients who underwent two-stage breast implant replacement [<a href="#rid50">50-55</a>]. However, the optimal type, side effects, and concentration of antimicrobial solutions remains unknown. Randomized studies with long-term follow-up are needed before we can recommend this approach.</p><p>The potential efficacy of treating breast implant infection with a one-stage implant replacement has been evaluated in retrospective studies [<a href="#rid56">56-62</a>]. As an example, in a study of 43 patients with infections where salvage was attempted with a one-stage replacement, 76.7 percent were successful with a mean follow-up of 18.4 months [<a href="#rid59">59</a>]. Salvage procedures included debridement, lavage, immediate prosthesis (eg, expander or permanent implant) replacement, and systemic antibiotics for four to six weeks tailored to culture and susceptibility results from the time of surgery. </p><p>In another retrospective cohort study of 73 microbiologically confirmed implant infections, implant pocket salvage was attempted in 43 patients, with either antibiotic therapy alone for approximately two weeks (n = 35) or antibiotics for three to four days followed by a one-stage replacement and additional antibiotics (n = 8) [<a href="#rid63">63</a>]. Successful salvage, defined as retention of implant ≥12 months after surgery, was higher with a one-stage replacement (100 percent) versus antibiotics alone (57 percent; p = 0.035). Successful salvage was higher in patients with infected tissue expanders versus implants. Given the small sample size and retrospective design, important limitations include treatment selection bias and lack of standardization in the outcome measures. For example, it is unclear whether any subjects with implant retention showed signs of a recurrence, chronic pain, or disfigurement [<a href="#rid50">50-55</a>]. </p><p class="headingAnchor" id="H2441011891"><span class="h4">Duration of antibiotic therapy</span><span class="headingEndMark"> — </span>Duration of therapy depends on the severity of infection and the surgical procedure employed. The initial course of intravenous antibiotics can be followed by a transition to oral therapy at 7 to 10 days if clinical improvement has occurred. The choice of subsequent oral antibiotic therapy, if indicated, is based on culture and sensitivity data recovered at the time of the surgical procedure.</p><p class="bulletIndent1"><span class="glyph">●</span>For deep infections treated with "one-stage" replacement, lavage, and/or debridement, we typically treat for two to four weeks. However, if <em>S. aureus</em> or coagulase-negative staphylococcus are cultured, the duration of antibiotic therapy should be extended to four to six weeks. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For deep infections treated with implant removal and debridement with plan for delayed reimplantation, we typically treat for 10 to 14 days for bacterial infections and three to six months for mycobacterial infections.</p><p></p><p class="headingAnchor" id="H10"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>We suggest against the <strong>routine</strong> use of antimicrobial prophylaxis for the prevention of surgical site infections. This is in agreement with a guidelines from multidisciplinary expert groups in the United States [<a href="#rid64">64</a>]. For patients with particular risk factors for infection (eg, diabetes mellitus, obesity, tobacco use, coexisting infections elsewhere, known colonization with microorganisms, immunocompromised), we and others administer prophylactic antibiotics. Many surgeons routinely give an intravenous antibiotic immediately prior to the procedure regardless of underlying risk factors. (See  <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults", section on 'Breast surgery'</a>.)</p><p>If prophylaxis is given for surgical site infection, it should cover the most common organisms responsible for wound infection, particularly staphylococci (see <a class="local">'Microbiology and epidemiology of infection'</a> above). The first-generation cephalosporin <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> (1 to 2 g intravenously) has been effective for most clean procedures [<a href="#rid65">65</a>]. A single dose should be given within 60 minutes prior to the surgical incision. (See  <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults", section on 'Antibiotic selection'</a>.)</p><p>The risk of surgical site infections with breast augmentation or reconstruction surgery is generally low. The estimated mean incidence of postoperative surgical site infection following augmentation surgery is 1.4 percent (range 0 to 1.7 percent) [<a href="#rid66">66</a>]. Infection rates are higher when all forms of breast reconstruction are included, ranging from 0 to 29 percent (average, 5.8 percent). </p><p>Several observational studies have explored the risk of infection with the use of perioperative antibiotics in breast implant surgery, with conflicting results [<a href="#rid66">66,67</a>]. With breast augmentation, perioperative antibiotic prophylaxis does not appear to reduce infection rates [<a href="#rid66">66</a>]. In a systematic review evaluating all forms of breast reconstruction, short courses (24 hours or less) of antibiotics were associated with reduced infection rates compared to no antibiotics [<a href="#rid67">67</a>]. However, longer courses of antibiotics were not associated with further reduction in rates of infection even when drains were in place [<a href="#rid68">68,69</a>]. </p><p>The use of topical antimicrobials and antiseptics for irrigation of the surgical pocket at the time of implantation has been suggested, but there are limited prospective clinical trials to support this practice [<a href="#rid70">70</a>]. Retrospective studies and limited prospective cohort studies have reported lower rates of surgical site infections and capsular contractures following irrigation of the implant pocket with a combination of antibiotics (eg, <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>, <a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">bacitracin</a>, and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>) and antiseptics (half-strength <a class="drug drug_general" data-topicid="9801" href="/z/d/drug information/9801.html" rel="external">povidone iodine</a>) [<a href="#rid71">71,72</a>]. One retrospective, single center study reported a low (0.5 percent) incidence of deep surgical site infection following primary breast augmentation without pocket irrigation. However, the study excluded breast cancer patients, all patients received one dose of perioperative systemic antibiotics, and the study did not include a comparator arm that received pocket irrigation [<a href="#rid73">73</a>]. Although not proven in controlled clinical trials, pocket irrigation with an antibiotic solution is commonly performed by most plastic surgeons.</p><p>For women with existing breast implants, there are no well-established strategies to reduce the risk of subsequent implant infection. Although prophylactic antibiotics are commonly given to such women prior to dental procedures, there are no data to support the practice [<a href="#rid74">74</a>] and we do not advise it, even with invasive dental procedures. For women with breast implants who need to undergo surgical procedures, the antibiotics typically given for that procedure to prevent surgical site infection should suffice. (See  <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults"</a>.)</p><p class="headingAnchor" id="H1381819274"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119871.html" rel="external">"Society guideline links: Breast surgery"</a>.)</p><p class="headingAnchor" id="H20459812"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Infections of breast implants occur in approximately 2 to 2.5 percent of cases. Postmastectomy implantation is associated with a higher risk of infection compared with breast augmentation alone. The use of particular surgical approaches or acellular dermal matrix may also increase the risk of infection. (See <a class="local">'Incidence and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most acute and subacute breast implant infections are due to gram-positive pathogens such as coagulase-negative staphylococci, <em>Cutibacterium</em> species, <em>Staphylococcus aureus</em>, and streptococci. Nontuberculous mycobacteria are also an important cause of subacute infections. Both gram-positive and gram-negative (eg, <em>Pseudomonas</em>) bacteria have been associated with late-onset infections, often secondary to bacteremia. (See <a class="local">'Microbiology and epidemiology of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breast implant infections usually have a bimodal presentation, during the acute postoperative period (six days to six weeks after surgery) or late onset (generally more than six months after surgery). Acute infections are usually associated with fever and breast pain, erythema, and drainage. Subacute infections may present with chronic pain, persistent drainage, failed healing of the incision site, or migration of the implant. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of breast implant infection is typically first suspected from the clinical features of fever and erythema of the breast. If the breast is increased in size or a seroma is suspected based on physical exam, an ultrasound should be performed. Any fluid present around the implant should be aspirated under ultrasound guidance and sent for Gram stain, aerobic and anaerobic bacterial cultures, and fungal and acid-fast bacilli smears and cultures. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some bacterial breast implant infections can be treated successfully with medical therapy alone. For those requiring surgical intervention, one-stage implant replacement is an option depending on the operative findings. However, implant removal with delayed reimplantation may be necessary for cure, particularly for mycobacterial and fungal infections. (See <a class="local">'Treatment'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with mild, superficial cellulitis (eg, no systemic symptoms and with a limited area of erythema overlying the breast), the oral empiric regimen should target methicillin-resistant <em>S. aureus </em>(MRSA), coagulase-negative staphylococcus, and streptococci. (See <a class="local">'Mild, superficial cellulitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with extensive cellulitis without involvement of the prosthesis, empiric therapy should be parenteral and include coverage for MRSA, coagulase-negative staphylococci, and streptococci. Surgical intervention is not necessary unless the patient fails to improve after 24 to 48 hours of antibiotics. (See <a class="local">'Extensive cellulitis and/or deep infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with breast implant infections who have evidence of systemic toxicity, involvement of the prosthesis, abscess or draining wound, we favor an empiric parenteral antibiotic therapy with a regimen effective against MRSA, coagulase-negative staphylococcus, and streptococci. If Gram stain or cultures reveal gram-negative organisms, coverage should be expanded to also cover gram-negative bacteria. Immediate surgical evaluation is also warranted in these cases. Duration of therapy depends on the infecting organism as well as the surgical approach. (See <a class="local">'Duration of antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a purulent, malodorous discharge or granulation tissue in the pocket, or with mycobacterial or fungal infection, a two-stage implant replacement with delayed reimplantation is favored. In the absence of these findings, a one-stage implant replacement with continued antibiotic therapy is usually attempted. (See <a class="local">'Surgical intervention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients undergoing breast augmentation or reconstructive surgery, we suggest against the <strong>routine</strong> use of antimicrobial prophylaxis for the prevention of surgical site infections (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with particular risk factors for infection (eg, diabetes mellitus, obesity, tobacco use, coexisting infections elsewhere, known colonization with microorganisms, immunocompromised), we do administer prophylactic antibiotics. (See <a class="local">'Prevention'</a> above and  <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lalani T. Breast Implant Infections: An Update. Infect Dis Clin North Am 2018; 32:877.</a></li><li class="breakAll">American Society of Plastic Surgeons. Plastic Surgery Statistics Report. https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic-surgery-statistics-full-report-2019.pdf (Accessed on July 15, 2020).</li><li><a class="nounderline abstract_t">Chun YS, Verma K, Rosen H, et al. Implant-based breast reconstruction using acellular dermal matrix and the risk of postoperative complications. Plast Reconstr Surg 2010; 125:429.</a></li><li><a class="nounderline abstract_t">Kjøller K, Hölmich LR, Jacobsen PH, et al. Epidemiological investigation of local complications after cosmetic breast implant surgery in Denmark. Ann Plast Surg 2002; 48:229.</a></li><li><a class="nounderline abstract_t">Jimenez RB, Packowski K, Horick N, et al. The Timing of Acute and Late Complications Following Mastectomy and Implant-based Reconstruction. Ann Surg 2023; 278:e203.</a></li><li><a class="nounderline abstract_t">Mesa F, Cataño S, Tuberquia O. Study of Infections in Breast Augmentation Surgery with Implants in 9,691 Patients over 5 Years. Plast Reconstr Surg Glob Open 2021; 9:e3752.</a></li><li><a class="nounderline abstract_t">Pittet B, Montandon D, Pittet D. Infection in breast implants. Lancet Infect Dis 2005; 5:94.</a></li><li><a class="nounderline abstract_t">Gabriel SE, Woods JE, O'Fallon WM, et al. Complications leading to surgery after breast implantation. N Engl J Med 1997; 336:677.</a></li><li><a class="nounderline abstract_t">Brand KG. Infection of mammary prostheses: a survey and the question of prevention. Ann Plast Surg 1993; 30:289.</a></li><li><a class="nounderline abstract_t">Olsen MA, Nickel KB, Fox IK, et al. Incidence of Surgical Site Infection Following Mastectomy With and Without Immediate Reconstruction Using Private Insurer Claims Data. Infect Control Hosp Epidemiol 2015; 36:907.</a></li><li><a class="nounderline abstract_t">Nahabedian MY, Tsangaris T, Momen B, Manson PN. Infectious complications following breast reconstruction with expanders and implants. Plast Reconstr Surg 2003; 112:467.</a></li><li><a class="nounderline abstract_t">Olsen MA, Nickel KB, Fox IK, et al. Comparison of Wound Complications After Immediate, Delayed, and Secondary Breast Reconstruction Procedures. JAMA Surg 2017; 152:e172338.</a></li><li><a class="nounderline abstract_t">Liu Q, Aggarwal A, Wu M, et al. Impact of diabetes on outcomes in breast reconstruction: A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg 2022; 75:1793.</a></li><li><a class="nounderline abstract_t">Martin MS, Kebede S, Saad OA, et al. Impact of Socioeconomic Status on Breast Reconstruction Outcomes. Ann Plast Surg 2022; 88:S481.</a></li><li><a class="nounderline abstract_t">Saldanha IJ, Broyles JM, Adam GP, et al. Implant-based Breast Reconstruction after Mastectomy for Breast Cancer: A Systematic Review and Meta-analysis. Plast Reconstr Surg Glob Open 2022; 10:e4179.</a></li><li><a class="nounderline abstract_t">Johnson AC, Colakoglu S, Siddikoglu D, et al. Impact of Dermal Matrix Brand in Implant-Based Breast Reconstruction Outcomes. Plast Reconstr Surg 2022; 150:17.</a></li><li><a class="nounderline abstract_t">Kummerow KL, Du L, Penson DF, et al. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 2015; 150:9.</a></li><li><a class="nounderline abstract_t">Merchant SJ, Goldstein L, Kruper LL. Patterns and Trends in Immediate Postmastectomy Reconstruction in California: Complications and Unscheduled Readmissions. Plast Reconstr Surg 2015; 136:10e.</a></li><li><a class="nounderline abstract_t">Zhao X, Wu X, Dong J, et al. A Meta-analysis of Postoperative Complications of Tissue Expander/Implant Breast Reconstruction Using Acellular Dermal Matrix. Aesthetic Plast Surg 2015; 39:892.</a></li><li><a class="nounderline abstract_t">Kainer MA, Keshavarz H, Jensen BJ, et al. Saline-filled breast implant contamination with Curvularia species among women who underwent cosmetic breast augmentation. J Infect Dis 2005; 192:170.</a></li><li><a class="nounderline abstract_t">Young VL, Hertl MC, Murray PR, et al. Microbial growth inside saline-filled breast implants. Plast Reconstr Surg 1997; 100:182.</a></li><li><a class="nounderline abstract_t">Chen NT, Butler PE, Hooper DC, May JW Jr. Bacterial growth in saline implants: in vitro and in vivo studies. Ann Plast Surg 1996; 36:337.</a></li><li><a class="nounderline abstract_t">Safranek TJ, Jarvis WR, Carson LA, et al. Mycobacterium chelonae wound infections after plastic surgery employing contaminated gentian violet skin-marking solution. N Engl J Med 1987; 317:197.</a></li><li><a class="nounderline abstract_t">Petit F, Maladry D, Werther JR, Mitz V. [Late infection of breast implant, complication of colonic perforation. Review of the literature. Role of preventive treatment]. Ann Chir Plast Esthet 1998; 43:559.</a></li><li><a class="nounderline abstract_t">Seng P, Bayle S, Alliez A, et al. The microbial epidemiology of breast implant infections in a regional referral centre for plastic and reconstructive surgery in the south of France. Int J Infect Dis 2015; 35:62.</a></li><li><a class="nounderline abstract_t">Lohmeyer JA, Jakob VL, Keck M, Wittig K. Antibiotic treatment and prophylaxis of periprosthetic infections: Evaluation of 666 consecutive breast implant removals. J Plast Reconstr Aesthet Surg 2021; 74:1486.</a></li><li><a class="nounderline abstract_t">Zhang R, Singh D, Parsa FD. Review of Early Signs of Breast Implant Infection. Aesthetic Plast Surg 2022; 46:2152.</a></li><li><a class="nounderline abstract_t">Teh JSK, Wilke AE, Overstall SM, et al. Prototheca wickerhamii breast implant infection after reconstructive surgery: a new level of complexity. Med Mycol Case Rep 2021; 34:22.</a></li><li><a class="nounderline abstract_t">Koan C, Venegas RJ, Murphy RA. A surprising complication of breast augmentation surgery. JPRAS Open 2022; 31:62.</a></li><li><a class="nounderline abstract_t">Ruffenach L, Bruant-Rodier C, Henry G, et al. [Pasteurellosis breast implant infection: A case report and literature review]. Ann Chir Plast Esthet 2021; 66:338.</a></li><li><a class="nounderline abstract_t">Nishikubo M, Nasu S, Maruoka H, et al. Sequential breast implant infections due to Campylobacter fetus subsp. fetus. J Infect Chemother 2021; 27:1080.</a></li><li><a class="nounderline abstract_t">Vedin T, Bergenfeldt H. Late Campylobacter jejuni mastitis after augmentation mammoplasty. JPRAS Open 2021; 30:13.</a></li><li><a class="nounderline abstract_t">Torres-Coy JA, Rodríguez-Castillo BA, Pérez-Alfonzo R, DE Waard JH. Source investigation of two outbreaks of skin and soft tissue infection by Mycobacterium abscessus subsp. abscessus in Venezuela. Epidemiol Infect 2016; 144:1117.</a></li><li><a class="nounderline abstract_t">Haiavy J, Tobin H. Mycobacterium fortuitum infection in prosthetic breast implants. Plast Reconstr Surg 2002; 109:2124.</a></li><li><a class="nounderline abstract_t">Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis 1982; 146:487.</a></li><li><a class="nounderline abstract_t">Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Invest 1984; 73:1191.</a></li><li><a class="nounderline abstract_t">Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318.</a></li><li><a class="nounderline abstract_t">Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33:1387.</a></li><li><a class="nounderline abstract_t">Vuong C, Gerke C, Somerville GA, et al. Quorum-sensing control of biofilm factors in Staphylococcus epidermidis. J Infect Dis 2003; 188:706.</a></li><li><a class="nounderline abstract_t">Thornton JW, Argenta LC, McClatchey KD, Marks MW. Studies on the endogenous flora of the human breast. Ann Plast Surg 1988; 20:39.</a></li><li><a class="nounderline abstract_t">Holm C, Mühlbauer W. Toxic shock syndrome in plastic surgery patients: case report and review of the literature. Aesthetic Plast Surg 1998; 22:180.</a></li><li><a class="nounderline abstract_t">Kim M, Ku I, Jin US. Diagnosis and management of toxic shock syndrome after breast reconstructive procedures with silicone implants. Arch Plast Surg 2021; 48:189.</a></li><li><a class="nounderline abstract_t">Pittman TA, Fan KL, Knapp A, et al. Comparison of Different Acellular Dermal Matrices in Breast Reconstruction: The 50/50 Study. Plast Reconstr Surg 2017; 139:521.</a></li><li><a class="nounderline abstract_t">Shah Z, Lehman JA Jr, Tan J. Does infection play a role in breast capsular contracture? Plast Reconstr Surg 1981; 68:34.</a></li><li><a class="nounderline abstract_t">Rudolph R, Woodward M. Absence of visible bacteria in capsules around silicone breast implants. Plast Reconstr Surg 1983; 72:32.</a></li><li><a class="nounderline abstract_t">Pajkos A, Deva AK, Vickery K, et al. Detection of subclinical infection in significant breast implant capsules. Plast Reconstr Surg 2003; 111:1605.</a></li><li><a class="nounderline abstract_t">Kanapathy M, Faderani R, Arumugam V, et al. Management of periprosthetic breast infection: a systematic review and meta-analysis. J Plast Reconstr Aesthet Surg 2021; 74:2831.</a></li><li><a class="nounderline abstract_t">Asaad M, Slovacek C, Mitchell D, et al. Surgical and Patient-Reported Outcomes of Autologous versus Implant-Based Reconstruction following Infected Breast Device Explantation. Plast Reconstr Surg 2022; 149:1080e.</a></li><li><a class="nounderline abstract_t">Schwartz JD. Salvage of infected implant-based breast reconstructions in morbidly obese patients with explantation and replacement with an autologous muscle-sparing latissimus dorsi flap. JPRAS Open 2022; 32:93.</a></li><li><a class="nounderline abstract_t">Antognoli LE, Singh DP, Choudhry S, et al. Rinse But Don't Repeat: Single Application V.A.C. VERAFLO Salvages Infected Breast Prostheses. Plast Reconstr Surg Glob Open 2021; 9:e3896.</a></li><li><a class="nounderline abstract_t">Faust E, Opoku-Agyeman JL, Behnam AB. Use of Negative-Pressure Wound Therapy With Instillation and Dwell Time: An Overview. Plast Reconstr Surg 2021; 147:16S.</a></li><li><a class="nounderline abstract_t">Haque S, Kanapathy M, Bollen E, et al. Patient-reported outcome and cost implication of acute salvage of infected implant-based breast reconstruction with negative pressure wound therapy with Instillation (NPWTi) compared to standard care. J Plast Reconstr Aesthet Surg 2021; 74:3300.</a></li><li><a class="nounderline abstract_t">Chicco M, Huang TC, Cheng HT. Negative-Pressure Wound Therapy in the Prevention and Management of Complications From Prosthetic Breast Reconstruction: A Systematic Review and Meta-analysis. Ann Plast Surg 2021; 87:478.</a></li><li><a class="nounderline abstract_t">Meybodi F, Sedaghat N, Elder E, et al. Salvaging the Unsalvageable: Negative Pressure Wound Therapy for Severe Infection of Prosthetic Breast Reconstruction. Plast Reconstr Surg Glob Open 2021; 9:e3456.</a></li><li><a class="nounderline abstract_t">Constantine T. Use of Negative-Pressure Wound Therapy With Instillation and Dwell in Breast Reconstruction. Plast Reconstr Surg 2021; 147:34S.</a></li><li><a class="nounderline abstract_t">Spear SL, Howard MA, Boehmler JH, et al. The infected or exposed breast implant: management and treatment strategies. Plast Reconstr Surg 2004; 113:1634.</a></li><li><a class="nounderline abstract_t">Kendrick AS, Chase CW. Salvage of an infected breast tissue expander with an implant sizer and negative pressure wound management. Plast Reconstr Surg 2008; 121:138e.</a></li><li><a class="nounderline abstract_t">Chun JK, Schulman MR. The infected breast prosthesis after mastectomy reconstruction: successful salvage of nine implants in eight consecutive patients. Plast Reconstr Surg 2007; 120:581.</a></li><li><a class="nounderline abstract_t">Prince MD, Suber JS, Aya-Ay ML, et al. Prosthesis salvage in breast reconstruction patients with periprosthetic infection and exposure. Plast Reconstr Surg 2012; 129:42.</a></li><li><a class="nounderline abstract_t">Agarwal S, Ettinger RE, Kung TA, et al. Cohort study of immediate implant exchange during acute infection in the setting of breast reconstruction. J Plast Reconstr Aesthet Surg 2017; 70:865.</a></li><li><a class="nounderline abstract_t">Asaad M, Slovacek C, Mitchell D, et al. Implant-Based Breast Reconstruction following Infected Device Explantation: Is a Second Attempt Worth It? Plast Reconstr Surg 2022; 150:247e.</a></li><li><a class="nounderline abstract_t">Falola RA, Shin HD, Monsivais SE, Czerwinski WL. Early versus Delayed Implant Exchange after Periprosthetic Breast Infection: A Single Center Study. Plast Reconstr Surg Glob Open 2021; 9:e3962.</a></li><li><a class="nounderline abstract_t">Franchelli S, Pesce M, Baldelli I, et al. Analysis of clinical management of infected breast implants and of factors associated to successful breast pocket salvage in infections occurring after breast reconstruction. Int J Infect Dis 2018; 71:67.</a></li><li><a class="nounderline abstract_t">Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195.</a></li><li><a class="nounderline abstract_t">Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett 2012; 10:73.</a></li><li><a class="nounderline abstract_t">Hardwicke JT, Bechar J, Skillman JM. Are systemic antibiotics indicated in aesthetic breast surgery? A systematic review of the literature. Plast Reconstr Surg 2013; 131:1395.</a></li><li><a class="nounderline abstract_t">Phillips BT, Halvorson EG. Antibiotic Prophylaxis following Implant-Based Breast Reconstruction: What Is the Evidence? Plast Reconstr Surg 2016; 138:751.</a></li><li><a class="nounderline abstract_t">Yamin F, Nouri A, McAuliffe P, et al. Routine Postoperative Antibiotics After Tissue Expander Placement Postmastectomy Does Not Improve Outcome. Ann Plast Surg 2021; 87:S28.</a></li><li><a class="nounderline abstract_t">Rothe K, Münster N, Hapfelmeier A, et al. Does the Duration of Perioperative Antibiotic Prophylaxis Influence the Incidence of Postoperative Surgical-Site Infections in Implant-Based Breast Reconstruction in Women with Breast Cancer? A Retrospective Study. Plast Reconstr Surg 2022; 149:617e.</a></li><li><a class="nounderline abstract_t">Baker NF, Brown O, Hart AM, et al. Preventing Infection in Implant-based Breast Reconstruction: Evaluating the Evidence for Common Practices and Standardized Protocols. Plast Reconstr Surg Glob Open 2022; 10:e4208.</a></li><li><a class="nounderline abstract_t">Araco A, Gravante G, Araco F, et al. Infections of breast implants in aesthetic breast augmentations: a single-center review of 3,002 patients. Aesthetic Plast Surg 2007; 31:325.</a></li><li><a class="nounderline abstract_t">Adams WP Jr, Rios JL, Smith SJ. Enhancing patient outcomes in aesthetic and reconstructive breast surgery using triple antibiotic breast irrigation: six-year prospective clinical study. Plast Reconstr Surg 2006; 117:30.</a></li><li><a class="nounderline abstract_t">Hemmingsen MN, Larsen A, Ørholt M, et al. Hematoma and deep surgical site infection following primary breast augmentation: A retrospective review of 1128 patients. J Plast Reconstr Aesthet Surg 2022; 75:1197.</a></li><li><a class="nounderline abstract_t">Stoopler ET, Sia YW, Kuperstein AS. Do patients with solid organ transplants or breast implants require antibiotic prophylaxis before dental treatment? J Can Dent Assoc 2012; 78:c5.</a></li></ol></div><div id="topicVersionRevision">Topic 5536 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30241714" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Breast Implant Infections: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30241714" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Breast Implant Infections: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124828" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Implant-based breast reconstruction using acellular dermal matrix and the risk of postoperative complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11862025" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiological investigation of local complications after cosmetic breast implant surgery in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35837894" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Timing of Acute and Late Complications Following Mastectomy and Implant-based Reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34386312" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Study of Infections in Breast Augmentation Surgery with Implants in 9,691 Patients over 5 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15680779" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Infection in breast implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041097" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Complications leading to surgery after breast implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8512282" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Infection of mammary prostheses: a survey and the question of prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26036877" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence of Surgical Site Infection Following Mastectomy With and Without Immediate Reconstruction Using Private Insurer Claims Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12900604" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Infectious complications following breast reconstruction with expanders and implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28724125" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of Wound Complications After Immediate, Delayed, and Secondary Breast Reconstruction Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35351394" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Impact of diabetes on outcomes in breast reconstruction: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35276707" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impact of Socioeconomic Status on Breast Reconstruction Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35317462" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Implant-based Breast Reconstruction after Mastectomy for Breast Cancer: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35499525" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impact of Dermal Matrix Brand in Implant-Based Breast Reconstruction Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25408966" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nationwide trends in mastectomy for early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26111325" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Patterns and Trends in Immediate Postmastectomy Reconstruction in California: Complications and Unscheduled Readmissions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26377821" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A Meta-analysis of Postoperative Complications of Tissue Expander/Implant Breast Reconstruction Using Acellular Dermal Matrix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942908" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Saline-filled breast implant contamination with Curvularia species among women who underwent cosmetic breast augmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207676" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Microbial growth inside saline-filled breast implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8728573" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bacterial growth in saline implants: in vitro and in vivo studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3600710" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mycobacterium chelonae wound infections after plastic surgery employing contaminated gentian violet skin-marking solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9882897" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : [Late infection of breast implant, complication of colonic perforation. Review of the literature. Role of preventive treatment].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25910855" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The microbial epidemiology of breast implant infections in a regional referral centre for plastic and reconstructive surgery in the south of France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33308989" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Antibiotic treatment and prophylaxis of periprosthetic infections: Evaluation of 666 consecutive breast implant removals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35091769" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Review of Early Signs of Breast Implant Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34584835" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prototheca wickerhamii breast implant infection after reconstructive surgery: a new level of complexity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34934794" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A surprising complication of breast augmentation surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34303485" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : [Pasteurellosis breast implant infection: A case report and literature review].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33563526" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sequential breast implant infections due to Campylobacter fetus subsp. fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34337129" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Late Campylobacter jejuni mastitis after augmentation mammoplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26441024" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Source investigation of two outbreaks of skin and soft tissue infection by Mycobacterium abscessus subsp. abscessus in Venezuela.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11994623" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mycobacterium fortuitum infection in prosthetic breast implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7119479" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pathogenesis of foreign body infection: description and characteristics of an animal model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6323536" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pathogenesis of foreign body infection. Evidence for a local granulocyte defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334980" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bacterial biofilms: a common cause of persistent infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11565080" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Biofilm formation: a clinically relevant microbiological process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12934187" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Quorum-sensing control of biofilm factors in Staphylococcus epidermidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341714" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Studies on the endogenous flora of the human breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9618183" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Toxic shock syndrome in plastic surgery patients: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33765737" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Diagnosis and management of toxic shock syndrome after breast reconstructive procedures with silicone implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28234811" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparison of Different Acellular Dermal Matrices in Breast Reconstruction: The 50/50 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7243998" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Does infection play a role in breast capsular contracture?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6867176" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Absence of visible bacteria in capsules around silicone breast implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12655204" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Detection of subclinical infection in significant breast implant capsules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34257035" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Management of periprosthetic breast infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35349553" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Surgical and Patient-Reported Outcomes of Autologous versus Implant-Based Reconstruction following Infected Breast Device Explantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35340710" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Salvage of infected implant-based breast reconstructions in morbidly obese patients with explantation and replacement with an autologous muscle-sparing latissimus dorsi flap.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34729288" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Rinse But Don't Repeat: Single Application V.A.C. VERAFLO Salvages Infected Breast Prostheses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33347059" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Use of Negative-Pressure Wound Therapy With Instillation and Dwell Time: An Overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34217644" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Patient-reported outcome and cost implication of acute salvage of infected implant-based breast reconstruction with negative pressure wound therapy with Instillation (NPWTi) compared to standard care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34060773" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Negative-Pressure Wound Therapy in the Prevention and Management of Complications From Prosthetic Breast Reconstruction: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33786259" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Salvaging the Unsalvageable: Negative Pressure Wound Therapy for Severe Infection of Prosthetic Breast Reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33347061" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Use of Negative-Pressure Wound Therapy With Instillation and Dwell in Breast Reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114123" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The infected or exposed breast implant: management and treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18317104" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Salvage of an infected breast tissue expander with an implant sizer and negative pressure wound management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17700107" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The infected breast prosthesis after mastectomy reconstruction: successful salvage of nine implants in eight consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22186499" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prosthesis salvage in breast reconstruction patients with periprosthetic infection and exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28478892" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cohort study of immediate implant exchange during acute infection in the setting of breast reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653515" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Implant-Based Breast Reconstruction following Infected Device Explantation: Is a Second Attempt Worth It?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35070604" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Early versus Delayed Implant Exchange after Periprosthetic Breast Infection: A Single Center Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29660396" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Analysis of clinical management of infected breast implants and of factors associated to successful breast pocket salvage in infections occurring after breast reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23327981" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical practice guidelines for antimicrobial prophylaxis in surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Antimicrobial prophylaxis for surgery</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23416440" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Are systemic antibiotics indicated in aesthetic breast surgery? A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27307337" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Antibiotic Prophylaxis following Implant-Based Breast Reconstruction: What Is the Evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33833164" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Routine Postoperative Antibiotics After Tissue Expander Placement Postmastectomy Does Not Improve Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35103626" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Does the Duration of Perioperative Antibiotic Prophylaxis Influence the Incidence of Postoperative Surgical-Site Infections in Implant-Based Breast Reconstruction in Women with Breast Cancer? A Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35350150" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Preventing Infection in Implant-based Breast Reconstruction: Evaluating the Evidence for Common Practices and Standardized Protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562098" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Infections of breast implants in aesthetic breast augmentations: a single-center review of 3,002 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16404244" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Enhancing patient outcomes in aesthetic and reconstructive breast surgery using triple antibiotic breast irrigation: six-year prospective clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34924323" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hematoma and deep surgical site infection following primary breast augmentation: A retrospective review of 1128 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22260809" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Do patients with solid organ transplants or breast implants require antibiotic prophylaxis before dental treatment?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
